These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1868 related articles for article (PubMed ID: 33725836)
21. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454 [TBL] [Abstract][Full Text] [Related]
22. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study]. Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837 [No Abstract] [Full Text] [Related]
23. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280 [TBL] [Abstract][Full Text] [Related]
24. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539 [TBL] [Abstract][Full Text] [Related]
25. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294 [TBL] [Abstract][Full Text] [Related]
26. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393 [TBL] [Abstract][Full Text] [Related]
27. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma. Wang JH; Wang H; Wang YJ; Xia ZJ; Huang HQ; Jiang WQ; Lu Y Oncotarget; 2016 Jun; 7(23):35412-22. PubMed ID: 27072578 [TBL] [Abstract][Full Text] [Related]
29. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study. Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928 [TBL] [Abstract][Full Text] [Related]
30. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study. Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707 [TBL] [Abstract][Full Text] [Related]
31. A five Vittayawacharin P; Khuhapinant A Hematology; 2021 Dec; 26(1):75-82. PubMed ID: 33427594 [TBL] [Abstract][Full Text] [Related]
32. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation]. Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704 [TBL] [Abstract][Full Text] [Related]
33. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Yang L; Liu H; Xu XH; Wang XF; Huang HM; Shi WY; Jiang SH Med Oncol; 2013 Dec; 30(4):720. PubMed ID: 24062259 [TBL] [Abstract][Full Text] [Related]
34. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010 [TBL] [Abstract][Full Text] [Related]
35. GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. Wang JJ; Dong M; He XH; Li YX; Wang WH; Liu P; Yang JL; Gui L; Zhang CG; Yang S; Zhou SY; Shi YK Medicine (Baltimore); 2016 Feb; 95(6):e2787. PubMed ID: 26871836 [TBL] [Abstract][Full Text] [Related]
36. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma. Jing XM; Zhang ZH; Wu P; Zhang SC; Ren YR; Xiong ZJ; Wei W; Luo L; Li L Leuk Res; 2016 Aug; 47():26-31. PubMed ID: 27239738 [TBL] [Abstract][Full Text] [Related]
38. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Wang L; Wang WD; Xia ZJ; Zhang YJ; Xiang J; Lu Y Med Oncol; 2014 Mar; 31(3):860. PubMed ID: 24481637 [TBL] [Abstract][Full Text] [Related]